Department of Biological Sciences, Monash University, Clayton, VIC, Australia.
Plant Cell Rep. 2011 May;30(5):789-98. doi: 10.1007/s00299-010-0995-5. Epub 2011 Jan 18.
Vaccines are one of the most successful public health achievements of the last century. Systematic immunisation programs have reduced the burden of infectious diseases on a global scale. However, there are limitations to the current technology, which often requires costly infrastructure and long lead times for production. Furthermore, the requirement to keep vaccines within the cold-chain throughout manufacture, transport and storage is often impractical and prohibitively expensive in developing countries-the very regions where vaccines are most needed. In contrast, plant-made vaccines (PMVs) can be produced at a lower cost using basic greenhouse agricultural methods, and do not need to be kept within such narrow temperature ranges. This increases the feasibility of developing countries producing vaccines locally at a small-scale to target the specific needs of the region. Additionally, the ability of plant-production technologies to rapidly produce large quantities of strain-specific vaccine demonstrates their potential use in combating pandemics. PMVs are a proven technology that has the potential to play an important role in increasing global health, both in the context of the 2015 Millennium Development Goals and beyond.
疫苗是上个世纪最成功的公共卫生成就之一。系统的免疫计划已经在全球范围内减轻了传染病的负担。然而,当前的技术存在局限性,通常需要昂贵的基础设施和长时间的生产准备。此外,在制造、运输和储存过程中保持疫苗处于冷链中的要求在发展中国家往往不切实际且极其昂贵——而这些正是最需要疫苗的地区。相比之下,植物制造的疫苗 (PMVs) 可以使用基本的温室农业方法以更低的成本生产,并且不需要保持在如此狭窄的温度范围内。这增加了发展中国家小规模生产疫苗以满足该地区具体需求的可行性。此外,植物生产技术能够快速生产大量针对特定菌株的疫苗,这表明它们在应对大流行方面具有潜在的用途。PMVs 是一种经过验证的技术,有可能在增加全球健康方面发挥重要作用,无论是在 2015 年千年发展目标的背景下还是在这之后。